Evidence map›Paper›PMID 37023503›Full record

ArticleMolecular genetics and metabolism2023

Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II.

Miles C Smith, Lalitha R Belur, Andrea D Karlen, Kelly Podetz-Pedersen, Olivia Erlanson, Kanut Laoharawee, Justin Furcich, Troy C Lund, Yun You, Davis Seelig and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular genetics and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Miles C SmithDepartment of Genetics, Cell Biology and Development, University Minnesota, Minneapolis, MN, United States; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Lalitha R BelurDepartment of Genetics, Cell Biology and Development, University Minnesota, Minneapolis, MN, United States; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Andrea D KarlenDepartment of Genetics, Cell Biology and Development, University Minnesota, Minneapolis, MN, United States; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Kelly Podetz-PedersenDepartment of Genetics, Cell Biology and Development, University Minnesota, Minneapolis, MN, United States; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Olivia ErlansonDepartment of Genetics, Cell Biology and Development, University Minnesota, Minneapolis, MN, United States; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Kanut LaoharaweeDepartment of Genetics, Cell Biology and Development, University Minnesota, Minneapolis, MN, United States; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Justin FurcichDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Troy C LundDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Yun YouMouse Genetics Laboratory, University of Minnesota, Minneapolis, MN, United States.
Davis SeeligComparative Pathology Shared Resource, University of Minnesota, St. Paul, MN, United States.
Beau R WebberCenter for Genome Engineering, University of Minnesota, Minneapolis, MN, United States; Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States; Stem Cell Institute, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
R Scott McIvorDepartment of Genetics, Cell Biology and Development, University Minnesota, Minneapolis, MN, United States; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States; Stem Cell Institute, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States. Electronic address: mcivo001@umn.edu.
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

NINDS Center Core at the University of MinnesotaP30NS062158 · NINDS · UNIVERSITY OF MINNESOTA · PI ORR, HARRY T. · 2011 to 2015
$3.5M
Stem Cell Biology Training ProgramT32GM113846 · NIGMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2015 to 2019
$712k
Multiplex Engineered Human Lymphocytes for Therapeutic Protein DeliveryR21AI163731 · NIAID · UNIVERSITY OF MINNESOTA · PI WEBBER, BEAU RICHARD · 2021 to 2022
$426k
NIAID NIH HHS R21 AI163731NIGMS NIH HHS T32 GM113846NINDS NIH HHS P30 NS062158
6 · The paper itself

Abstract

Mucopolysaccharidosis type II (Hunter syndrome, MPS II) is an inherited X-linked recessive disease caused by deficiency of iduronate-2-sulfatase (IDS), resulting in the accumulation of the glycosaminoglycans (GAG) heparan and dermatan sulfates. Mouse models of MPS II have been used in several reports to study disease pathology and to conduct preclinical studies for current and next generation therapies. Here, we report the generation and characterization of an immunodeficient mouse model of MPS II, where CRISPR/Cas9 was employed to knock out a portion of the murine IDS gene on the NOD/SCID/Il2rγ (NSG) immunodeficient background. IDS

Indexed as

Iduronate SulfataseMucopolysaccharidosis IIAnimalsGlycosaminoglycansHumansMiceMice, Inbred NODMice, SCIDGlycosaminoglycansIduronate SulfataseCRISPR/Cas9GlycosaminoglycansHunter syndromeIduronate-2-sulfataseMucopolysaccharidosis type IINSG

Identifiers

PMID37023503
PMCPMC10705040
OpenAlexW4319970117

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.